Skip to content

Study maps tumours’ need for sugar for mobility.

Cancer cells are gluttons. Researchers have long known that they monopolize large amounts of sugar. More recently, it became clear that some tumour cells are also characterized by a series of features such as mobility or unlikeliness to join in an ordered set. Researchers are calling this behaviour ‘mesenchymal,’ and they suspect it promotes metastasis.

At EPFL, a research team was able to demonstrate that the two observations, appetite for sugar and mesenchymal behaviour, result from the same mechanism, at least in non-small cell lung cancer.  They also showed that the intensity of the phenomenon significantly influenced the chances of patient survival. Published in Cancer & Metabolism, this discovery opens up new potential targets for future therapies.

Mesenchymal behaviour is not in itself an anomaly. During embryonic development, some cells acquire these characteristics. In adults, a few cells retain this disposition.  Mesenchymal behaviour is quite a useful feature, but it’s abnormally reactivated in non-small cell lung cancer in the current study.

The mesenchymal cancer cells studied by the researchers produce a protein called GLUT3. The latter serves the function of capturing glucose to activate various growth processes. This is the protein responsible for meeting the cell’s need for sugar.

By artificially inducing mesenchymal behaviour in cancer cells, the researchers found that the cells spontaneously produced GLUT3. This observation clearly shows that the same mechanism is at work.  This shift from one behaviour to another, called epithelial-mesenchymal transition, is a highly debated issue. The team have clearly established a cause and effect relationship between this transition and the glucose consumption of cancer cells.

Lung tumour cells produce widely varying amounts of GLUT3. This is because the gene is itself regulated by an element called ZEB1, and the amount of the latter is a function of many causes.  These variations in the amounts of GLUT3 seem to be a strong indicator of the aggressiveness of the tumour. By analyzing data from 450 patients with metastatic non-small cell lung cancer, researchers were able to show that the larger the quantity of GLUT3, the lower the chances of survival.

Patients were diagnosed relatively early and were followed for several years. Depending on whether they produced high or low amounts of GLUT3, their survival rates over seven years spanned almost 20%.   The data didn’t permit the team to conclude that the mechanism promotes metastasis, but greatly reinforces the theory.

The discovery identifies a potential target for future medications.  For example, a toxic molecule that could be specifically incorporated by GLUT3 to destroy the cell from within.  Protected by the blood-brain barrier, neurons that also produce GLUT3 would not be affected.

Source:  École polytechnique fédérale de Lausanne EPFL


GLUT3 is strongly expressed in mesenchymal lung tumor cells.   The indicated cells were stained to analyze the expression of GLUT3 or E-cadherin by immunocytochemistry. Scale bar, 100 μm.  The dashed line indicates the separation between the mesenchymal and the epithelial groups of cells.  Meylan et al 2014.
GLUT3 is strongly expressed in mesenchymal lung tumour cells. The indicated cells were stained to analyze the expression of GLUT3 or E-cadherin by immunocytochemistry. Scale bar, 100 μm. The dashed line indicates the separation between the mesenchymal and the epithelial groups of cells. Meylan et al 2014.

Healthinnovations View All

Michelle Petersen is the founder of Healthinnovations, having worked in the health and science industry for over 21 years, which includes tenure within the NHS and Oxford University. Healthinnovations is a publication that has reported on, influenced, and researched current and future innovations in health for the past decade.

Michelle has been picked up as an expert writer for Informa publisher’s Clinical Trials community, as well as being listed as a blog source by the world’s leading medical journals, including the acclaimed Nature-Springer journal series.

Healthinnovations is currently indexed by the trusted Altmetric and PlumX metrics systems, respectively, as a blog source for published research globally. Healthinnovations is also featured in the world-renowned BioPortfolio,, the life science, pharmaceutical and healthcare portal.

Most recently the Texas A&M University covered The Top 10 Healthinnovations series on their site with distinguished Professor Stephen Maren calling the inclusion of himself and his team on the list a reflection of “the hard work and dedication of my students and trainees”.

Michelle Petersen’s copy was used in the highly successful marketing campaign for the mega-hit film ‘Jumanji: The Next Level, starring Jack Black, Karen Gilian, Kevin Hart and Dwayne ‘The Rock’ Johnson. Michelle Petersen’s copywriting was part of the film’s coverage by the Republic TV network. Republic TV is the most-watched English language TV channel in India since its inception in 2017.

An avid campaigner in the fight against child sex abuse and trafficking, Michelle is a passionate humanist striving for a better quality of life for all humans by helping to provide traction for new technologies and techniques within healthcare.

One thought on “Study maps tumours’ need for sugar for mobility. Leave a comment

  1. Wow, fantastic blog layout! How long have you been blogging for?
    you make bloggingg look easy. The overall look of your
    website is magnificent, as well as the content!

Leave a Reply

Translate »